Therapeutic potential of CD20 x CD3 bispecific antibodies

FHS
April 5, 2024
5:24 am

On Monday, March 25th, 2024, the U.S. FDA declined approval for Regeneron’s Odronextamab for two forms of lymphoma due to concerns over the progress of ongoing confirmatory trials.

RHÖN-KLINIKUM AG publishes result for first half of 2023 – outlook confirmed – Biotech Investments

EQS-News: RHÖN-KLINIKUM Aktiengesellschaft / Key word(s): Half Year Results/Miscellaneous RHÖN-KLINIKUM Aktiengesellschaft: RHÖN-KLINIKUM AG publishes result for first half of 2023 – outlook confirmed 10.08.2023 /

August 11, 2023

Accenture Federal Services Wins $190M Contract to Support PEPFAR’s Global Fight Against AIDS

What You Should Know: – Accenture Federal Services has been awarded a substantial $190 million contract from the U.S. Department of State. – The company

September 19, 2024

New peptide library paves the way for targeting elusive cancer factor MYC

Researchers developed a second-generation NTB bicyclic peptide library, identifying NT-B2R, a peptide that effectively targets MYC, a key factor in most human cancers, demonstrating its

January 8, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.